Peter J. O’Dwyer - Concepedia

Author

Peter J. O’Dwyer

Also Known As

Asselin, Eric, Gregory J. Tsongalis, O'Dwyer, Peter J, P J O'Dwyer, P O'Dwyer, P. J. O'Dwyer, P. J. O’Dwyer, P. O'Dwyer, P. ODwyer, P. OʼDwyer

769

Publications

41.8K

Citations

H-Index

171

Concepts

All Affiliations

University of Pennsylvania Fox Chase Cancer Center Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Massachusetts General Hospital

About

Peter J. O’Dwyer is an author at University of Pennsylvania specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	140	9.2K
2	Health Sciences	19	27	2K
3	Natural Sciences	8	8	472
4	Education	1	1	285
5	Engineering	1	1	285

Peter J. O’Dwyer

265

Publications

38.8K

Citations

H-Index

Page 1

	Year	Citations
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky, Kotb Abdelmohsen, Akihisa Abe, Autophagy	2016	5.9K
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, New England Journal of Medicine	2010	3.5K
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Journal of Clinical Oncology	2007	2.3K
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans Gregory L. Beatty, E. Gabriela Chiorean, Matthew P. Fishman, Science	2011	1.6K
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy Mara H. Sherman, Ruth T. Yu, Dannielle D. Engle, Cell Tumor BiologyPancreatic CancerMedicinePharmacologyGastroenterology	2014	1.1K
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2006	1K
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer Scott Kopetz, Jayesh Desai, Emily Chan, Journal of Clinical Oncology	2015	678
Phase II Trial of Sorafenib in Advanced Thyroid Cancer Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore, Journal of Clinical Oncology	2008	676
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Tim Eisen, T. Ahmad, Keith T. Flaherty, British Journal of Cancer	2006	633
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Cancer Discovery	2018	563

Page 1